You are here

Engineered T-cells show promise

Chimeric antigen receptor (CAR)-T-cells are a concept in development for treating cancer. Seattle researchers have published a new approach for developing CAR-T-cells. This new strategy could eventually lead to better outcomes for people living with HIV.

What is a CAR-T cell?

T-cell receptors help trigger immune responses. T-cell receptors are found on the surface of T cells, extending inside the cell to signal to other molecules. CAR-T cells have an engineered T-cell receptor. In a CAR-T-cell, the outer and inner segments of the receptor come from different molecules.

Why develop this approach for HIV?

Antiretroviral drugs don’t completely get rid of HIV infection. Natural immune responses are also not able to clear lingering virus. CAR-T-cells might be able to do what regular T cells can’t — kill HIV-infected cells remaining in the body during therapy. This is because CAR-T-cells recognise a broad range of HIV-infected cells, are potent and may be less affected by the blocks limiting regular T cells. CAR-T-cells have already been developed and tested in people living with HIV. Clinical trials of first-generation CAR-T-cells showed that the cells stay in the body for more than ten years, but do not reduce the amount of virus.

What’s different this time?

In the recent study, the outer segment of the T-cell receptor included parts of broadly neutralising antibodies (bNAbs) which effectively target multiple HIV strains. The researchers used an inner segment of the T-cell receptor from normal T cells, with co-stimulatory components that weren’t included in the first-gen CAR-T-cells. The researchers made the CAR-T-cells resistant to HIV infection by directing the T-cell receptor genes to the middle of the CCR5 gene. The engineered cells specifically targeted HIV-infected cells, and were resistant to HIV infection.

What exactly did the researchers do?

First, the researchers created CAR-T-cells from healthy human T cells using five different bNAbs. The researchers then tested the cells in a range of experiments. The CAR-T-cells became activated in the presence of HIV-infected cells, and could kill HIV-infected cells.

Secondly, the researchers selected the most potent CAR-T variant (PGT145-CAR) to test CCR5 disruption. Similar to the first lot of CAR-T-cells, the CCR5-edited CAR-T-cells were activated and could kill HIV-infected cells. In addition, the CCR5-edited CAR-T-cells were better at dealing with active virus replication.

What does this all mean?

This work shows the potential for engineered T-cells based on broadly neutralising antibodies that are themselves resistant to HIV infection.

These cells are specifically switched on when they encounter HIV antigens. They are able to kill HIV-infected cells even when there is a lot of HIV around because they don’t get infected and can maintain their potent function.

This work is still at an early stage. All of the experiments in this study were done in laboratory models of disease. The CCR5-edited CAR-T-cells haven’t been tested in humans yet. Recent funding announcements suggest that there is a lot of preclinical exploration of this promising strategy to come.

For the latest science visit HIV Cure

latest news

April 19, 2017
Researchers are collating stories of family life in the context of HIV, hepatitis B and hepatitis C.
March 7, 2017
“For me, being told that I couldn’t have children was harder than the diagnosis itself."
March 7, 2017
"People in heterosexual relationships seem to think that HIV could never affect them — but it does.”
March 1, 2017
In a major breakthrough, scientists in Geelong have discovered a protein that could prevent HIV. 
February 1, 2017
This is a film that delves into a not-too-distant time when the gay community was devastated by HIV/AIDS.
January 30, 2017
Sydney's Albion Centre is providing free mindfulness sessions for people living with HIV.
January 24, 2017
A survey is being conducted to better understand the experience and challenges of living with HIV.
January 17, 2017
During the holiday break, the HIV community sadly lost one of its most beloved leaders.
January 17, 2017
Young heterosexual people living with HIV are among the most isolated in the positive community.
January 12, 2017
PrEP will be made available to 2,000 Queenslanders at risk of HIV this year; access sites are recruiting now. 
January 9, 2017
The Positive Living team would appreciate it if you could find the time to complete a short online survey. 
December 16, 2016
Four, simple, practical actions you can take to stay happy, healthy and connected over the holiday season.
December 12, 2016
MyLife+ is a world-first app for PLHIV, with unique tools to help PLHIV take more control of their health.
December 7, 2016
It's a story we hear less often. but one that deserves to be heard. Two women with HIV share their stories. 
December 6, 2016
Gaëtan Dugas — the man dubbed ‘Patient Zero’ has, after more than three decades, been exonerated.